Aryl-N-Aryl Antiviral Compounds for RNA Replication Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are few effective treatments for RNA virus infections, particularly those caused by single-stranded RNA viruses belonging to Group IV and Group V of the Baltimore classification, with existing therapies primarily focused on symptom relief rather than cure.
Innovation Solution
Aryl-N-aryl compounds are developed to exhibit broad-spectrum activity against RNA viruses, specifically targeting single-stranded RNA viruses in Groups IV and V, including Chikungunya, Dengue, and Influenza viruses, through chemical synthesis processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used for RNA virus infections, then symptom relief is provided, but effective treatment and cure are not achieved
Solution Approach 1:
The invention segments the broad problem of RNA virus treatment by developing compounds that specifically target the replication step in the viral life cycle. The aryl-N-aryl derivatives are designed to interfere with viral RNA replication machinery, separating the therapeutic action from general symptom management and providing targeted antiviral efficacy against Groups IV and V RNA viruses.
Solution Approach 2:
The invention changes the therapeutic parameter from symptomatic relief to antiviral replication inhibition. The aryl-N-aryl compounds modify the biochemical parameters of viral replication by interfering with RNA synthesis, thereby transforming the treatment approach from palliative to curative for RNA virus infections.
2Adaptability or versatility
If broad-spectrum antiviral compounds are developed, then coverage against multiple RNA viruses is achieved, but specificity and targeted efficacy may be reduced
Solution Approach 1:
The aryl-N-aryl compounds exhibit universality by demonstrating broad-spectrum activity against multiple RNA virus groups (Groups IV and V). The molecular structure is designed to interact with conserved elements of the viral replication machinery that are common across different RNA virus families, enabling a single compound class to address multiple pathogens effectively.
Solution Approach 2:
The invention uses the viral replication machinery itself as an intermediary target. The aryl-N-aryl compounds do not directly attack the virus particle but rather interfere with the replication process by targeting the enzymatic activities required for RNA synthesis, thereby achieving broad-spectrum efficacy through a common mechanistic pathway.
Data Source
AI summary
A compound of formula (Ie):wherein Y1 represents an aryl group, X2 represents a —O— group, a —NH— group, a —S— group, a —CO—NH— group, a —NH—CO—NH— group, a —NH—CO— group, a —CH(OH)— group, a —CH(COOH)NH— group, a —CH(COOCH3)NH— group, a —C(OH)(CH2OH)—, agroup, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or heteroatoms, a —SO2— group, or a —SO2—NH— group, Y2 represents a hydrogen atom, a hydroxyl group, a (C1-C4)alkoxy group, a —CHC(OH)2, a COORf, wherein Rf represents a hydrogen atom or a (C1-C4)alkyl group, a morpholinyl group, a dihydropyranyl group, agroup, agroup, a —PO(ORf)(OR′f) group, wherein Rf and R′f independently represents a hydrogen atom or a (C1-C4)alkyl group, an oxetanyl group, a —Si(CH3)3 group, a —NHCOO—(C1-C4)alkyl group, or a —CR1R2R3 group, or any of its pharmaceutically acceptable salt and pharmaceutical compositions containing them and to synthesis process for manufacturing them.